NASDAQ:XOMA - XOMA Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $14.91 +0.90 (+6.42 %) (As of 11/21/2018 03:08 PM ET)Previous Close$14.01Today's Range$14.19 - $15.1052-Week Range$11.88 - $37.25Volume2,470 shsAverage Volume126,618 shsMarket Capitalization$118.01 millionP/E Ratio15.33Dividend YieldN/ABeta2.75 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California. Receive XOMA News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:XOMA Previous Symbol CUSIP98419J10 Webwww.xoma.com Phone510-204-7200 Debt Debt-to-Equity Ratio19.16 Current Ratio5.38 Quick Ratio5.38 Price-To-Earnings Trailing P/E Ratio15.33 Forward P/E Ratio-9.15 P/E GrowthN/A Sales & Book Value Annual Sales$52.69 million Price / Sales2.37 Cash Flow$2.2523 per share Price / Cash6.62 Book Value$0.14 per share Price / Book106.50 Profitability EPS (Most Recent Fiscal Year)$0.98 Net Income$14.59 million Net Margins-129.85% Return on Equity-267.64% Return on Assets-26.53% Miscellaneous Employees12 Outstanding Shares8,390,000Market Cap$118.01 million OptionableNot Optionable XOMA (NASDAQ:XOMA) Frequently Asked Questions What is XOMA's stock symbol? XOMA trades on the NASDAQ under the ticker symbol "XOMA." How were XOMA's earnings last quarter? XOMA Corp (NASDAQ:XOMA) issued its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.40. The biotechnology company had revenue of $0.90 million for the quarter, compared to analyst estimates of $0.83 million. XOMA had a negative return on equity of 267.64% and a negative net margin of 129.85%. View XOMA's Earnings History. When is XOMA's next earnings date? XOMA is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for XOMA. What price target have analysts set for XOMA? 3 equities research analysts have issued 12 month target prices for XOMA's stock. Their forecasts range from $16.26 to $36.00. On average, they expect XOMA's stock price to reach $28.42 in the next twelve months. This suggests a possible upside of 89.6% from the stock's current price. View Analyst Price Targets for XOMA. What is the consensus analysts' recommendation for XOMA? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XOMA. What are Wall Street analysts saying about XOMA stock? Here are some recent quotes from research analysts about XOMA stock: 1. HC Wainwright analysts commented, "Valuation disconnect continues even when considering a limited set of current assets. Regarding our valuation of XOMA we believe that the current share price is currently disconnected from the underlying value of even just its opportunity from Novartis (NVS; not rated) partnered assets, led by canakinumab (Ilaris)." (9/21/2018) 2. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (8/11/2018) Has XOMA been receiving favorable news coverage? News headlines about XOMA stock have been trending somewhat positive on Wednesday, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. XOMA earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next several days. Who are some of XOMA's key competitors? Some companies that are related to XOMA include Kura Oncology (KURA), Corium International (CORI), Kezar Life Sciences (KZR), Obseva (OBSV), Rigel Pharmaceuticals (RIGL), Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP), TG Therapeutics (TGTX), BioSpecifics Technologies (BSTC), Dova Pharmaceuticals (DOVA), Odonate Therapeutics (ODT), Kindred Biosciences (KIN), Sinovac Biotech (SVA), Xeris Pharmaceuticals (XERS) and Akebia Therapeutics (AKBA). Who are XOMA's key executives? XOMA's management team includes the folowing people: Mr. James R. Neal, CEO & Director (Age 62)Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 44)Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 42)Dr. Kirk W. Johnson, VP of Devel. (Age 58)Dr. Deepshikha Datta, Chief Bus. Officer Who are XOMA's major shareholders? XOMA's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.39%), Acadian Asset Management LLC (1.21%), GSA Capital Partners LLP (0.65%), Dimensional Fund Advisors LP (0.64%), Macquarie Group Ltd. (0.62%) and Bank of New York Mellon Corp (0.60%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, John Varian, Ness W Denman Van, Patrick J Md Phd Scannon, Thomas M Burns and Value Fund L P Biotechnology. View Institutional Ownership Trends for XOMA. Which institutional investors are selling XOMA stock? XOMA stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., O Shaughnessy Asset Management LLC and Globeflex Capital L P. Company insiders that have sold XOMA company stock in the last year include James R Neal, Ness W Denman Van and Thomas M Burns. View Insider Buying and Selling for XOMA. Which institutional investors are buying XOMA stock? XOMA stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, GSA Capital Partners LLP, Jefferies Group LLC, Bank of New York Mellon Corp, Acadian Asset Management LLC and BlackRock Inc.. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal and Value Fund L P Biotechnology. View Insider Buying and Selling for XOMA. How do I buy shares of XOMA? Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is XOMA's stock price today? One share of XOMA stock can currently be purchased for approximately $14.99. How big of a company is XOMA? XOMA has a market capitalization of $118.01 million and generates $52.69 million in revenue each year. The biotechnology company earns $14.59 million in net income (profit) each year or $0.98 on an earnings per share basis. XOMA employs 12 workers across the globe. What is XOMA's official website? The official website for XOMA is http://www.xoma.com. How can I contact XOMA? XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected] MarketBeat Community Rating for XOMA (NASDAQ XOMA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 333 (Vote Outperform)Underperform Votes: 303 (Vote Underperform)Total Votes: 636MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/21/2018 by MarketBeat.com StaffFeatured Article: What does cost of debt say about a company’s financial health?